Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
Times cited: 58
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Proceedings of the National Academy of Sciences of the United States of America.
Times cited: 87